報價延遲最少15分鐘:2026/04/25 05:36 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.69 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-36.48/0.73
|
|
企業價值
84.44M
|
| 資產負債 |
|
每股賬面淨值
-29.54
|
| 現金流量 |
|
現金流量率
0.05
|
| 損益表 |
|
收益
30.25M
|
|
每股收益
6.61
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. |
